Just ten seconds more. I think it's seventeen past, so I think we'll start the presentation. So thank you for affording the presentation. This Third Quarter Revenue Presentation, which is also the nine months, first nine months of 2024 revenue for the Cegedim Group. So on a nine-month basis, the sales, the revenue amounts to EUR 475.8 million, on a growth of 5.9% reported, 4.3% like- for- like. On the third quarter, especially, the revenues are EUR 156.8 million, so it's a growth of 5.7% reported and 3.8% like- for- like. As you may have noticed, the organic growth for the two last quarters, so the third quarter and the second quarter, around 3.3% and 3.8% like- for- like, a bit less than our full- year target. And this is mainly due to the comparison effect of the subsidies that we received last year for the Ségur de la Santé. We have the occasion to elaborate a bit more on this during the presentation. The main contributors were marketing, BPO, HR, and cloud solutions. And on the significant events that happened during the quarter, the main one is the new financing arrangement that we announced on July 31st, and that we put there on this slide as a reminder for you. On the third quarter, 2024, you can see on the left-hand side, the bridge of growth. It's mainly organic growth, 3.8% growth, organic, and, structure impact is EUR 2.7 million, so it's a growth of 1.8%, and is mainly due to the integration of Visiodent. The currency impact, positive, is due to the sterling pound. As you can see on the right-hand side, it is the bridge, per division of the growth. Almost all the division contributed during this quarter. On the Software and Services, was just slightly down at -0.5%, and we'll talk about it later on. On the nine months basis, the growth is mainly organic, so it's 4.3% organic growth. Structure impact, still Visiodent increase impact, the sterling pound. On this nine months bridge, growth per division, Software and Services, Flow, Data Marketing, BPO, Cloud and Support. So it means all the division contributed positively to the growth, even though Software and Services was a bit timid compared to the others. I suggest that we dive into the various division and see what happened during the quarter and the nine months. Per division, as you know, is the Software and Services, that, on the nine months basis, generated a revenue of EUR 227.7 million, sorry. And on the third quarter, a revenue of EUR 75.6 million. So, on Cegedim, so the various subdivision that you know, Cegedim Santé. So we have, as I mentioned, earlier on, we have a strong impact of Ségur de la Santé on the nine months basis. The subsidies were mainly during Q2 and Q3 last year. However, you can see that even though the organic growth is - 9.8%, it's improving quarter- on- quarter on Cegedim Santé. Also, the gap between the like-for-like growth and the released growth, the published growth, is due to the integration of Visiodent since March 1st. That also generates synergies among the group. On the other French subsidiaries, so the pharmacists especially had a difficult nine months. On the third quarter also, because of the comparison with Ségur de la Santé, for which it had received last year grants of EUR 2 million, and also because last year, due to the Ségur de la Santé, lots of pharmacists bought some equipment, and so that this year, there are less sales in equipment. However, in the subdivision, HR and insurance are performing quite well during for the nine months and during the quarter. So it means the subdivision has a growth of 0.9% on the nine months basis. Last, international activities. As expected, sales are a bit down on this, on this nine months revenue. This is due, as I mentioned, during the previous calls. It's due to the strategic move from Cegedim on the U.K. doctors to refocus on Scotland, meaning getting out of the market in England, Northern Ireland, and Wales, so these are the first impacts on revenue, as expected, and as you probably expected, too. The second division that we'll talk about is Flow, the Flow division. So, on year to date, on the first nine months, it generated a revenue of EUR 73.2 million, a growth of 5.7% reported, 5.6% like- for- like, and on the Q3, EUR 23.7 million, a growth of 5.5%, reported 5.4% like- for- like. So as you can see, e-business had a growth of 5.1% on a nine-month basis, which is a good growth and interesting growth, even though Q3 was a bit shy compared to the rest of the year, and also for the nine months. This is due, as you can remember, that the French reform on electronic invoices was postponed last year from 2024 to 2026. So it means that also that our clients are less of an urge to migrate to our solutions. But still, it's a good growth on a nine-month basis. Also, third-party payer generated a growth of 6.7% on the nine first months of 2024. This is due to volume in Q1, but also due to the success of its offering in fraud and long-term illness detection. The third division is Data and Marketing. As you can see, data is flattish in growth on the first nine months. The division is up of 10.8%, mainly due to the marketing. That, I will elaborate a bit more. The nine months revenue is EUR 87.5 million, growth of 10.8%, as I mentioned. On Q3, growth is 17%, generating a revenue of EUR 28.2 million. As I said, data is flattish on this first nine months, - 0.7%. France is a bit more dynamic than international, as we mentioned in earlier calls. Marketing had a very, very strong first nine months and a very strong Q3. This is due to two things. For the nine months, it's due to its strategy, phygital strategy, with a good offering and a good demand on print and digital. During the Q3, it led some special ad campaigns, so during the Olympics, meaning that that resulted in a growth of 38% on the third quarter for marketing. All in, it's a growth of 10.8% on nine months for this division. The fourth division is the BPO, the outsourcing. As you see, and as you know, the insurance BPO had very strong first nine-month growth. This is due partly to a favorable comparison stemming from the Allianz contract. As you know, it started last year on April 1st, but it also had a very good dynamic for its overflow business. On the business services BPO, the growth was 6.5% on 9 months. This is due to the good success, to the important success of its compliance offering. Also, reaching to new clients and a good momentum from the existent customer base. All in, it's a growth of 18.8% reported and like- for- like on 9 months basis, so it's EUR 61.5 million revenue, and on Q3, it was EUR 21.6 million, a growth of 13.9% reported and like-for-like. Then we have the division that we are named Cloud and Support. Still very good growth, very important growth of 13.9%, on nine months and EUR 25.8 million of revenue. On the Q3, it had an interesting growth of 12.5% reported and like-for-like, so it is a revenue of EUR 7.7 million, meaning that its sovereign cloud-backed products and services are still enjoy still a very good momentum. Regarding our outlook for the year, we keep the same outlook of a growth range from 5%-8% like-for-like. But as you can see in our figures, we probably most probably be in the lower part of the range. And on the recurring operating income, we still expect an increase on this year compared to last year. And last slide is the financial agenda for next year, for 2025, with our sales revenues, and you have it also on our website. I suggest that we can dive into the questions, and we'll ask you to raise your hand if you have some question to ask us about this revenue presentation. So I think we have Gabriel. Gabriel, the floor is yours. Yes. Can you hear me? Yes, very well. Yes, thanks for the presentation. Just one question for me. Do you have any visibility on 2025 growth, organic growth, concerning Cegedim and for the group, too, please? It's too early. Budgets are not finished, so- But you- I cannot answer. Yeah. Okay, okay. The growth there won't be any exceptional items, except the fact that the revenue coming from the U.K. will decrease strongly. So globally, the growth rate will be very small. The impact will be positive on the EBIT and EBITDA side, but we are going to lose our revenue in the U.K. Okay. And any news for the wave two of Ségur de la Santé? No. We with, It is always on negotiation. It should start in the second half of next year and on the Paramed. But the amount of the subsidies is still on negotiation with the authorities. So we are going to be very cautious in our budgets and our estimation for next year. We're thinking like EUR 5 million of sales or something like that? Yeah. If it starts effectively in second half, having a gain of EUR 5 million is really achievable. Yeah. Okay. Very clear. Thanks. Thank you. Okay. Eric, I think you raised your hand, so please, you can ask your question. Do you hear me? Yes, we can hear you. Hello and good evening. Just, first of all, very good quarter on marketing. It's, we can expect this kind of growth on the fourth quarter? No. No, because in the past the revenue between half July and end of August was almost zero because the announcements the company which make announcements advertisement they don't want to pay for this period because all the people are in holidays on holidays. So it was really exceptional due to the Olympic Games and due to the fact that we have created some specific presentation into the pharmacies near the Olympic where the Olympic Games sites. Sites, yes. Okay. So, it got- Should be something like, not far from, to double- digit, but the growth should be around 10% and not as high as we have- On the fourth quarter? Yeah. Okay. And, any news about, Maiia offer? I've seen... I have heard that, Equasens, want to launch, a kind of product Yeah similar to Maiia. Yes. And- CompuGroup launched such a product two years ago, and they had no success. So yes, we have competitors. But they, in fact, Today we are the real and main competitor to Doctolib, and we are gaining market share. Not as much as we expected, because we expected to have a growth this year, which would compensate the fact that we have had no subsidies. And we know that it's gonna be difficult to Match the subsidies- to match subsidies. Ségur de la Santé? Yeah, yeah, so as we, as you see, end of second quarter, we were at - 12%. End of third quarter, we are - 9%, so it should be. It It should improve in the fourth quarter, but we now think that we won't reach the +0% we had as a target, meaning that the growth of the business would compensate the fact that we have no subsidies. We will be a few million euros under. When you say that you are the second one in front of Doctolib, what kind of market share that means for you in front of Doctolib? Oh, well, Just an idea. It's not... but it's very small. I don't want to be, I think we are not far from 10% of the market. And Doctolib? Doctolib is, let's say, 35% or 40%. Half of the doctors, they don't have, they don't use those agenda tools, so we think that there are still some room, some places for us. But the Doctolib is very well known. Yeah, yeah. It's a problem for you. A problem. It's, it's really a problem, but okay. Okay. You see, Doctolib is now seen as a very dominant market position by more and more doctors. Since our prices are below their prices, we have some transfer from Doctolib to Maiia. Almost one-third of our gain comes from Doctolib. It is true that we grow. We would expect to grow more, but Doctolib is a real competitor, is a real company, well installed. And the last point is on Great Britain. How it works, your decline, it's continuing slowly or it's working well? As you can see, it is slow because the doctors need to be transferred to the competitor's software, and to do that, we need the help of the NHS, and they seem to be reluctant to push doctors to migrate, so what we do is to reduce our staff in order to be just able to maintain the existing software. We don't make any development anymore. That's the reason why we have a plan where the losses we are making are going to decrease, but we know that it will take minimum three years, well, 2.5 years now, to go out from the market. With a slow decline at the beginning? Yeah. Okay. We have the same problem, I would say, in Scotland, where we are the unique agreed provider, agreed by the NSS, the National Services Scotland. But then, we have 50% of the market. We should grow because the NSS should push the doctors who are equipped by the competitor's software to our software, but it's also slow, so it's a long process. Okay, thank you. But the goal is really to reduce, as quickly as possible, those losses we have on this market. Okay. Thank you very much. Thank you. You're welcome. Is there any other question? Eric, you have another one? No, sorry. Okay, no problem. I forgot to. It's okay. Okay. Thank you. So I don't see any other questions, so I guess we have been clear. Okay. So, let me thank you for attending the presentation. If you were to have some more question, you can contact me at investorrelations@cegedim.com. Thank you very much, and have a good evening, and see you, see you next time. Thank you very much. Thank you. Bye bye. Bye-bye. Bye.